VIVUS LLC

VIVUS LLC, on behalf of its subsidiary VIVUS BV, is pleased to announce the availability of QSIVA® (phentermine and topiramate modified-release) hard capsules in Poland as of November 29th, 2024 for the treatment of weight management in certain adults. For more information, including the Qsiva Summary of Product Characteristics for Poland, please visit: https://lnkd.in/ePp4j-ZK #obesitymedicine #treatingobesity #vivusllc #vivusbv About QSIVA QSIVA is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol. The effect of QSIVA on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of QSIVA in combination with other products intended for weight loss, including prescription and over-thecounter drugs and herbal preparations, have not been established. For more information on QSIVA, please visit QSIVA.eu. QSIVA is marketed as QSYMIA® (phentermine and topiramate extended-release capsules) CIV in the United States. Important Safety Information for QSIVA/QSYMIA QSIVA/QSYMIA is contraindicated in pregnancy and in women of childbearing potential who are not using effective methods of contraception; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors; or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in QSIVA/QSYMIA. QSIVA/QSYMIA can cause fetal harm. It is recommended that patients who can become pregnant obtain a negative pregnancy test result before starting QSIVA/QSYMIA treatment, perform monthly pregnancy testing, and use effective contraception while taking QSIVA/QSYMIA. If a patient becomes pregnant while taking QSIVA/QSYMIA, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus. The most common adverse reactions to QSIVA/QSYMIA in adults are paraesthesia, dizziness, an altered or impaired sense of taste, insomnia, constipation, and dry mouth. For non-U.S. healthcare professionals, information about QSIVA can be found at QSIVA.eu. For U.S. healthcare professionals, information about QSYMIA can be found at QSYMIA.com including its approved use in certain pediatric patients ages 12-17.

VIVUS will be closed November 28-29, 2024 for the Thanksgiving holiday in the United States. You can still find us online at VIVUS.com. We’ll reopen for normal business hours on Monday, December 2nd, 2024. Have a Happy Thanksgiving! We hope you get to enjoy time with your loved ones. #HappyThanksgiving #Thanksgiving #vivusllc

VIVUS LLC, on behalf of its subsidiary VIVUS BV, is pleased to announce the availability of QSIVA® (phentermine and topiramate modified-release) hard capsules in Iceland as of November 27th, 2024 for the treatment of weight management in certain adults. For more information, including the Qsiva Summary of Product Characteristics for Iceland, please visit: https://lnkd.in/ePp4j-ZK #obesitymedicine #treatingobesity #vivusllc #vivusbv About QSIVA QSIVA is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol. The effect of QSIVA on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of QSIVA in combination with other products intended for weight loss, including prescription and over-thecounter drugs and herbal preparations, have not been established. For more information on QSIVA, please visit QSIVA.eu. QSIVA is marketed as QSYMIA® (phentermine and topiramate extended-release capsules) CIV in the United States. Important Safety Information for QSIVA/QSYMIA QSIVA/QSYMIA is contraindicated in pregnancy and in women of childbearing potential who are not using effective methods of contraception; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors; or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in QSIVA/QSYMIA. QSIVA/QSYMIA can cause fetal harm. It is recommended that patients who can become pregnant obtain a negative pregnancy test result before starting QSIVA/QSYMIA treatment, perform monthly pregnancy testing, and use effective contraception while taking QSIVA/QSYMIA. If a patient becomes pregnant while taking QSIVA/QSYMIA, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus. The most common adverse reactions to QSIVA/QSYMIA in adults are paraesthesia, dizziness, an altered or impaired sense of taste, insomnia, constipation, and dry mouth. For non-U.S. healthcare professionals, information about QSIVA can be found at QSIVA.eu. For U.S. healthcare professionals, information about QSYMIA can be found at QSYMIA.com including its approved use in certain pediatric patients ages 12-17.

VIVUS LLC, on behalf of its subsidiary VIVUS BV, is pleased to announce the availability of QSIVA® (phentermine and topiramate modified-release) hard capsules in Finland as of November 24th, 2024 for the treatment of weight management in certain adults. For more information, including the Qsiva Summary of Product Characteristics for Finland, please visit: https://lnkd.in/ePp4j-ZK #obesitymedicine #treatingobesity #vivusllc #vivusbv About QSIVA QSIVA is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol. The effect of QSIVA on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of QSIVA in combination with other products intended for weight loss, including prescription and over-thecounter drugs and herbal preparations, have not been established. For more information on QSIVA, please visit QSIVA.eu. QSIVA is marketed as QSYMIA® (phentermine and topiramate extended-release capsules) CIV in the United States. Important Safety Information for QSIVA/QSYMIA QSIVA/QSYMIA is contraindicated in pregnancy and in women of childbearing potential who are not using effective methods of contraception; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors; or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in QSIVA/QSYMIA. QSIVA/QSYMIA can cause fetal harm. It is recommended that patients who can become pregnant obtain a negative pregnancy test result before starting QSIVA/QSYMIA treatment, perform monthly pregnancy testing, and use effective contraception while taking QSIVA/QSYMIA. If a patient becomes pregnant while taking QSIVA/QSYMIA, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus. The most common adverse reactions to QSIVA/QSYMIA in adults are paraesthesia, dizziness, an altered or impaired sense of taste, insomnia, constipation, and dry mouth. For non-U.S. healthcare professionals, information about QSIVA can be found at QSIVA.eu. For U.S. healthcare professionals, information about QSYMIA can be found at QSYMIA.com including its approved use in certain pediatric patients ages 12-17.

According to the Pancreatic Cancer Action Network (PanCAN), pancreatic cancer remains one of the most challenging cancers to prevent, diagnose or treat. Its risk factors and symptoms are unfamiliar to most. And with no standard test to find pancreatic cancer early in the general population, it is often diagnosed late when fewer treatment options are available. November is Pancreatic Cancer Awareness Month. During this time PanCAN Ambassadors come together for an important message about the importance of knowing your symptoms, knowing your family history and knowing your risk. Join PanCAN during Pancreatic Cancer Awareness Month and help change the course of pancreatic cancer. To learn more and to get involved, visit: https://lnkd.in/gHgYWX-x According to the Cleveland Clinic, pancreatic cancer is a leading cause of EPI (Exocrine Pancreatic Insufficiency) in adults. VIVUS is committed to working with gastroenterology professionals and associations in order to build awareness of EPI and provide treatment options to help patients manage this lifelong condition. Visit VIVUS.com to learn more about our work in this area. #WageHope #treatingEPI #ExocrinePancreaticInsufficiency #vivusllc

November 21, 2024 is the 10 year anniversary of World Pancreatic Cancer Day. The World Pancreatic Cancer Coalition says “Hello Pancreas” to invite everyone to learn more about their pancreas and create a global conversation about pancreatic cancer. Their goal on this important date is to continue the conversation about this deadly disease and address a general lack of knowledge about the pancreas. Visit https://lnkd.in/d_heGF2V to learn more and get involved. According to the Cleveland Clinic, pancreatic cancer is a leading cause of EPI (Exocrine Pancreatic Insufficiency) in adults. VIVUS is committed to working with gastroenterology professionals and associations in order to build awareness of EPI and provide treatment options to help patients manage this lifelong condition. Visit VIVUS.com to learn more about our work in this area. #WPCD #HelloPancreas #treatingEPI #ExocrinePancreaticInsufficiency #vivusllc

A new study in Journal of the American Heart Association (AHA) finds that abdominal body fat could hint at cardiovascular disease risk even when other health factors are not considered. The research highlights the potential role of the body roundness index — a measure to reflect abdominal body fat and height that some healthcare professionals believe better reflects the proportion of body fat and visceral fat than body mass index — may help to predict a person’s risk of developing cardiovascular disease. The article notes that obesity is a significant modifiable risk factor for cardiovascular disease, and previous research has indicated that abdominal obesity may be a stronger risk factor for cardiovascular disease than general obesity. Read the AHA's press release and find links to the study at: https://bit.ly/4etn4RI VIVUS is committed to advancing treatment options for obesity and offering much-needed hope to adult and pediatric patients globally. To learn more about our work in this area, please visit VIVUS.com. #treatingobesity #obesitymedicine #vivusllc #weightmanagement #weightlossmedications

VIVUS and PharmaAccess are proud to be Gold Sponsors at the 6th UAE Obesity Conference & 1st WOF MENA Conference on 16-17 November 2024 at the Rosewood Hotel in Abu Dhabi. This international conference will feature some of the most prominent speakers from around the world, supported by the World Obesity Federation, ADPHC, and DCT Abu Dhabi. The event promises to be a significant gathering for experts and professionals in the field of obesity and healthcare. To learn more visit: https://lnkd.in/eX798WH4 VIVUS and PharmaAccess are sponsoring the workshop “The Evolution of the Treatment Landscape for Overweight & Obesity” on Sunday, November 17, 2024 which will feature Dr. Andres Acosta M.D., Ph.D. and Dr. Anthony Auriemma MD, JD, FOMA. We invite conference attendees to attend this discussion which will focus on practical knowledge and strategies that can be applied in clinical practice. VIVUS is committed to advancing treatment options for obesity and offering much-needed hope to adult and pediatric patients globally. To learn more about our work in this area, please visit VIVUS.com. PharmaAccess’s mission is to improve patients' lives by identifying and commercializing innovative products that address unmet medical needs. PharmaAccess provides VIVUS with comprehensive solutions, managing key functions in marketing, sales, distribution, regulatory affairs, medical affairs, and pharmacovigilance. https://lnkd.in/e73-3G54 Disclosure: Dr. Acosta and Dr. Auriemma provide consulting services to VIVUS LLC. #6UOC #obesitymedicine #treatingobesity #vivusllc

World Diabetes Day (WDD) is the world's largest diabetes awareness campaign reaching a global audience of over 1 billion people in over 160 countries. It is marked every year on 14 November, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922. WDD was created in 1991 by International Diabetes Federation (IDF) and the World Health Organization and became an official United Nations Day in 2006 with the passage of United Nations Resolution 61/225. Diabetes and well-being is the theme of WWD 2024. Diabetes can affect every part of a person’s life, often having a negative impact on their wellbeing. Support for the person’s well-being should be prioritised in diabetes care. Find out all the different ways you can get involved in this year’s campaign please visit: https://lnkd.in/fw_QdAA As the American Diabetes Association notes, having overweight or obesity raises the risk for type 2 diabetes, heart disease, and stroke. VIVUS is committed to advancing treatment options for overweight and obesity — offering much-needed hope to adult and pediatric patients globally. To learn more about our work in this area, please visit VIVUS.com. #DiabetesLife #WorldDiabetesDay #treatingobesity #obesitymedicine #vivusllc #weightmanagement #weightlossmedications

This Veterans Day, we honor the military veterans of the United States Armed Forces and acknowledge their contributions to our national security. 🇺🇸 🫡 👏 Although Veterans Day is a federal holiday, VIVUS will be open on Monday, November 11th, 2024 and as always, you can find us online at VIVUS.com.